Rakovina Therapeutics Secures $1.5 Million Financing and Appoints New CEO to Advance Cancer Drug Pipeline
核心洞察
Rakovina Therapeutics (搜索) announced up to $1.5 million in new financing through a $1 million convertible debenture and $500,000 private placement to support near-term operations and strategic initiatives.
The company appointed Kim Oishi as Chief Executive Officer and Frank Holler as independent director, strengthening leadership and governance capabilities.
Existing convertible debenture holders consented to extend the maturity date from January 28, 2026 to March 11, 2026, providing additional time for debt restructuring.
Rakovina Therapeutics (搜索) Inc. announced a comprehensive corporate restructuring plan including up to $1.5 million in new financing, key leadership appointments, and debt optimization measures to support its oncology drug development programs. The Vancouver-based biopharmaceutical company disclosed the strategic initiatives on January 27, 2026, as it advances novel cancer therapies targeting the DNA damage response pathway.
Financing Strategy Addresses Near-Term Capital Needs
The company secured an agreement in principle for a $1 million convertible debenture financing from an existing investor, featuring a three-year maturity until January 28, 2029, and a conversion price of $0.20 per common share. The debenture carries a 12% annual interest rate payable quarterly in cash or common shares at the holder's discretion.
Concurrently, Rakovina proposed a $500,000 non-brokered private placement offering up to 5,000,000 common shares at $0.12 per share. The combined proceeds will provide working capital to support ongoing corporate activities and strategic initiatives while the company evaluates longer-term financing alternatives.
For every $50,000 principal amount issued in the convertible debenture, the company will issue 100,000 common share purchase warrants exercisable at $0.20 per share until January 28, 2029.
Debt Restructuring Provides Operational Flexibility
Holders of the company's outstanding 12% convertible debentures totaling $1,454,000 in principal consented to extend the maturity date from January 28, 2026 to March 11, 2026. The extension was approved by holders representing at least 66⅔% of the outstanding principal in accordance with the debenture indenture terms.
Rakovina reached an agreement in principle with one debenture holder to convert $1 million of outstanding principal plus $50,000 in accrued interest into new replacement debentures on substantially similar terms to the 2026 debenture. The company also intends to offer existing holders the opportunity to settle outstanding obligations through a shares-for-debt conversion at $0.12 per common share, subject to regulatory approval.
Leadership Changes Strengthen Governance
Kim Oishi was appointed Chief Executive Officer and will join the board of directors, bringing extensive experience in public company leadership, capital markets strategy, and corporate governance. "I am excited to become part of the Rakovina team and to build on the strong scientific foundation already in place," Oishi stated. "The Company has generated compelling preclinical data, supported by recent conference presentations and high-quality AI-driven drug-discovery collaborations."
Frank Holler joined the board as an independent director, contributing decades of biotechnology industry experience. Holler co-founded ID Biomedical Corp., which GlaxoSmithKline acquired in 2005, and served as founding director of Angiotech Pharmaceuticals and co-founder and initial CEO of Xenon Pharmaceuticals, now a NASDAQ-listed company with multiple late-stage clinical programs.
Most recently, Holler served as Chair of Theratechnologies Inc., contributing to its strategic positioning and successful acquisition by CB Biotech LLC (搜索) for $254 million in September 2025. "The Company's recent scientific presentations and its expanded collaboration with Variational AI (搜索), particularly around the KT-5000 (搜索) series of next-generation ATR inhibitors, underscore the quality of the work being done," Holler commented.
Jeffrey Bacha, co-founder of Rakovina, continues as non-executive Board Chair while serving as CEO and Director of Edison Oncology (搜索) Holding Corp., which has filed for an initial public offering in the United States. Edison Oncology is currently Rakovina's largest shareholder.
Scientific Focus on DNA Damage Response
Rakovina Therapeutics (搜索) focuses on developing innovative cancer treatments targeting the DNA damage response pathway. The company leverages advanced computational chemistry and artificial intelligence-enabled drug discovery platforms to accelerate the identification and optimization of novel oncology therapeutics.
The company's pipeline includes the KT-5000 (搜索) series of next-generation ATR inhibitors, developed through an expanded collaboration with Variational AI (搜索). Recent conference presentations have highlighted the company's preclinical progress in this therapeutic area.
Dr. Dennis Brown stepped down from the board due to increasing responsibilities as Chair of Edison Oncology (搜索) but continues as Chair of Rakovina's Scientific Advisory Committee, ensuring ongoing scientific continuity across research programs.
All proposed transactions remain subject to regulatory approvals, including approval from the TSX Venture Exchange, and the execution of definitive agreements. Securities issued in connection with the financing and debt restructuring will be subject to a statutory hold period of four months plus one day from the date of issuance under applicable Canadian securities laws.